In honor of March Madness, the Motley Fool's health-care team assembled their own bracket consisting of the 16 largest and best pharmaceutical and biotech stocks on the market. The series kicks off with a tough matchup between two of the biggest players in the diabetes space: Sanofi and Eli Lilly . To learn the bull and bear cases for each stock -- and to see which stock will move on to the Elite Eight -- watch the following video.
Is Eli Lilly a buy or sell?
With two of its top three drugs poised to lose patent protection this year, is Eli Lilly a dividend stock headed nowhere fast? In a new premium report, The Motley Fool's senior pharmaceuticals analyst breaks down all of Lilly's moving parts, including an in-depth analysis of the company's must-know opportunities and reasons to buy and sell today. To find out more click here to claim your copy today.
The article Market Madness Showdown: Sanofi vs. Eli Lilly originally appeared on Fool.com.
David Williamson, Max Macaluso, Ph.D., and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.